- Home
- FBNC vs IRON Comparison
FBNC vs IRON Comparison
Compare FBNC & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- IRON
- Stock Information
- Founded
- FBNC 1934
- IRON 2017
- Country
- FBNC United States
- IRON United States
- Employees
- FBNC N/A
- IRON N/A
- Industry
- FBNC Major Banks
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- FBNC Finance
- IRON Health Care
- Exchange
- FBNC Nasdaq
- IRON Nasdaq
- Market Cap
- FBNC 2.2B
- IRON 2.1B
- IPO Year
- FBNC N/A
- IRON N/A
- Fundamental
- Price
- FBNC $51.19
- IRON $68.02
- Analyst Decision
- FBNC Buy
- IRON Strong Buy
- Analyst Count
- FBNC 4
- IRON 10
- Target Price
- FBNC $56.67
- IRON $97.80
- AVG Volume (30 Days)
- FBNC 220.5K
- IRON 340.9K
- Earning Date
- FBNC 10-22-2025
- IRON 11-11-2025
- Dividend Yield
- FBNC 1.80%
- IRON N/A
- EPS Growth
- FBNC N/A
- IRON N/A
- EPS
- FBNC 2.35
- IRON N/A
- Revenue
- FBNC $361,053,000.00
- IRON N/A
- Revenue This Year
- FBNC $36.30
- IRON N/A
- Revenue Next Year
- FBNC $8.19
- IRON N/A
- P/E Ratio
- FBNC $21.81
- IRON N/A
- Revenue Growth
- FBNC N/A
- IRON N/A
- 52 Week Low
- FBNC $34.50
- IRON $30.82
- 52 Week High
- FBNC $56.45
- IRON $69.87
- Technical
- Relative Strength Index (RSI)
- FBNC 36.87
- IRON 66.16
- Support Level
- FBNC $51.91
- IRON $65.26
- Resistance Level
- FBNC $53.41
- IRON $69.87
- Average True Range (ATR)
- FBNC 1.13
- IRON 2.52
- MACD
- FBNC -0.33
- IRON 0.54
- Stochastic Oscillator
- FBNC 1.51
- IRON 80.55
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.